Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	39.5	45.82	7.27	8.19	20.3	16.74
Short-Term Investments	13.75	14.4	-	4.93	-	-
Cash & Short-Term Investments	53.25	60.21	7.27	13.12	20.3	16.74
Cash Growth	648.03%	728.67%	-44.62%	-35.38%	21.31%	26.66%
Other Current Assets	0.5	0.08	0.07	0.05	0.22	0.06
Total Current Assets	53.75	60.29	7.33	13.17	20.52	16.8
Property, Plant & Equipment	0.12	-	0.01	0.06	-	-
Other Long-Term Assets	-	-	-	-	-	0.07
Total Assets	53.87	60.29	7.35	13.23	20.52	16.87
Accounts Payable	1.55	2.25	1.76	3.13	1.58	1.18
Accrued Expenses	-	3	-	-	-	-
Total Current Liabilities	1.58	5.25	1.76	3.13	1.58	1.18
Long-Term Leases	0.08	-	-	0.01	-	-
Total Liabilities	1.66	5.25	1.76	3.14	1.58	1.18
Common Stock	0.01	0.01	0	0.01	0.01	0.01
Additional Paid-In Capital	132.99	130.79	65.81	61.87	60.22	47.87
Retained Earnings	-80.87	-75.79	-60.21	-51.8	-41.29	-32.19
Comprehensive Income & Other	0.08	0.04	-0.01	0.01	-0	-0.01
Total Common Equity	52.2	55.04	5.59	10.09	18.94	15.69
Shareholders' Equity	52.2	55.04	5.59	10.09	18.94	15.69
Total Liabilities & Equity	53.87	60.29	7.35	13.23	20.52	16.87
Total Debt	0.11	-	-	0.01	-	-
Net Cash (Debt)	53.14	60.21	7.27	13.11	20.3	16.74
Net Cash Growth	646.43%	728.67%	-44.58%	-35.42%	21.31%	26.66%
Net Cash Per Share	9.47	15.89	2.63	5.15	8.14	7.64
Filing Date Shares Outstanding	6.17	6.11	3.49	2.64	2.52	2.51
Total Common Shares Outstanding	6.13	6.1	2.98	2.59	2.52	2.29
Working Capital	52.16	55.04	5.58	10.04	18.94	15.62
Book Value Per Share	8.52	9.02	1.87	3.90	7.52	6.85
Tangible Book Value	52.2	55.04	5.59	10.09	18.94	15.69
Tangible Book Value Per Share	8.52	9.02	1.87	3.90	7.52	6.85

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q